Related references
Note: Only part of the references are listed.Ixazomib, an oral proteasome inhibitor, exhibits potential effect in dystrophin-deficient mdx mice
Maria Laura Jorge Micheletto et al.
INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY (2021)
Genetic Modifiers of Duchenne Muscular Dystrophy in Chinese Patients
Menglong Chen et al.
FRONTIERS IN NEUROLOGY (2020)
Restorative treatments of dystrophin expression in Duchenne muscular dystrophy: A systematic review
Carlos Pascual-Morena et al.
ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY (2020)
The ACTN3 577XX Null Genotype Is Associated with Low Left Ventricular Dilation-Free Survival Rate in Patients with Duchenne Muscular Dystrophy
Masashi Nagai et al.
JOURNAL OF CARDIAC FAILURE (2020)
Myostatin inhibition promotes fast fibre hypertrophy but causes loss of AMP-activated protein kinase signalling and poor exercise tolerance in a model of limb-girdle muscular dystrophy R1/2A
Irina Kramerova et al.
JOURNAL OF PHYSIOLOGY-LONDON (2020)
The Failed Clinical Story of Myostatin Inhibitors against Duchenne Muscular Dystrophy: Exploring the Biology behind the Battle
Emma Rybalka et al.
CELLS (2020)
A child with duchenne muscular dystrophy: A case report of a rare diagnosis among Africans
David D. Nassoro et al.
CLINICAL CASE REPORTS (2020)
Sudden cardiac death of Duchenne muscular dystrophy with NT-proBNP in pericardial fluid as a useful biomarker for diagnosis of the cause of death: a case report
Mengzhou Zhang et al.
FORENSIC SCIENCES RESEARCH (2020)
CARDIAC INJURY FROM ASYMPTOMATIC DUCHENNE MUSCULAR DYSTROPHY
Iok Fai Cheang et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2019)
Role of Transforming Growth Factor- in Skeletal Muscle Fibrosis: A Review
Ahmed Ismaeel et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Chain-Shortened Myostatin Inhibitory Peptides Improve Grip Strength in Mice
Kentaro Takayama et al.
ACS MEDICINAL CHEMISTRY LETTERS (2019)
A GDF11/myostatin inhibitor, GDF11 propeptide-Fc, increases skeletal muscle mass and improves muscle strength in dystrophic mdx mice
Quan Jin et al.
SKELETAL MUSCLE (2019)
The Usual Suspects: Genes for Inflammation, Fibrosis, Regeneration, and Muscle Strength Modify Duchenne Muscular Dystrophy
Luca Bello et al.
JOURNAL OF CLINICAL MEDICINE (2019)
Long-term natural history data in Duchenne muscular dystrophy ambulant patients with mutations amenable to skip exons 44, 45, 51 and 53
Claudia Brogna et al.
PLOS ONE (2019)
Long-range genomic regulators of THBS1 and LTBP4 modify disease severity in duchenne muscular dystrophy
Robert B. Weiss et al.
ANNALS OF NEUROLOGY (2018)
DMD mutation and LTBP4 haplotype do not predict onset of left ventricular dysfunction in Duchenne muscular dystrophy
Charlotte S. Van Dorn et al.
CARDIOLOGY IN THE YOUNG (2018)
DMD genotype correlations from the Duchenne Registry: Endogenous exon skipping is a factor in prolonged ambulation for individuals with a defined mutation subtype
Richard T. Wang et al.
HUMAN MUTATION (2018)
How glucocorticoids change life in Duchenne muscular dystrophy
Nathalie Goemans
LANCET (2018)
Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management (vol 17, pg 251, 2018)
J. F. Zimmermann et al.
LANCET NEUROLOGY (2018)
Myostatin and activin blockade by engineered follistatin results in hypertrophy and improves dystrophic pathology in mdx mouse more than myostatin blockade alone
Andrea Iskenderian et al.
SKELETAL MUSCLE (2018)
Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management
David J. Birnkrant et al.
LANCET NEUROLOGY (2018)
MYOSTATIN INHIBITOR ACE-031 TREATMENT OF AMBULATORY BOYS WITH DUCHENNE MUSCULAR DYSTROPHY: RESULTS OF A RANDOMIZED, PLACEBO- CONTROLLED CLINICAL TRIAL
Craig Campbell et al.
MUSCLE & NERVE (2017)
A current approach to heart failure in Duchenne muscular dystrophy
Domenico D'Amario et al.
HEART (2017)
A systematic review of risk factors associated with muscular dystrophies
Caroline Barakat-Haddad et al.
NEUROTOXICOLOGY (2017)
Genetic modifiers of muscular dystrophy act on sarcolemmal resealing and recovery from injury
Mattia Quattrocelli et al.
PLOS GENETICS (2017)
A mouse anti-myostatin antibody increases muscle mass and improves muscle strength and contractility in the mdx mouse model of Duchenne muscular dystrophy and its humanized equivalent, domagrozumab (PF-06252616), increases muscle volume in cynomolgus monkeys
Michael St. Andre et al.
SKELETAL MUSCLE (2017)
Transforming growth factor beta (TGF-β) mediates cardiac fibrosis and induces diabetic cardiomyopathy
Yiyang Yue et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2017)
Association Study of Exon Variants in the NF-κB and TGFβ Pathways Identifies CD40 as a Modifier of Duchenne Muscular Dystrophy
Luca Bello et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2016)
Osteopontin ablation ameliorates muscular dystrophy by shifting macrophages to a pro-regenerative phenotype
Joana Capote et al.
JOURNAL OF CELL BIOLOGY (2016)
Management of scoliosis in patients with Duchenne muscular dystrophy and spinal muscular atrophy: A literature review
Sumeet Garg
JOURNAL OF PEDIATRIC REHABILITATION MEDICINE (2016)
Genetic Modifiers of Ambulation in the Cooperative International Neuromuscular Research Group Duchenne Natural History Study
Luca Bello et al.
ANNALS OF NEUROLOGY (2015)
Modifier genes and their effect on Duchenne muscular dystrophy
Andy H. Vo et al.
CURRENT OPINION IN NEUROLOGY (2015)
Chronic effects of losartan on the muscles and the serologic profiles of mdx mice
Eun-Mi Lee et al.
LIFE SCIENCES (2015)
Validation of genetic modifiers for Duchenne muscular dystrophy: a multicentre study assessing SPP1 and LTBP4 variants
Janneke C. van den Bergen et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2015)
Genetic Modifiers of Duchenne Muscular Dystrophy and Dilated Cardiomyopathy
Andrea Barp et al.
PLOS ONE (2015)
Fixed or random effects meta-analysis? Common methodological issues in systematic reviews of effectiveness
Catalin Tufanaru et al.
INTERNATIONAL JOURNAL OF EVIDENCE-BASED HEALTHCARE (2015)
Restoration of muscle strength in dystrophic muscle by angiotensin-1-7 through inhibition of TGF-β signalling
Maria Jose Acuna et al.
HUMAN MOLECULAR GENETICS (2014)
Eccentric muscle challenge shows osteopontin polymorphism modulation of muscle damage
Whitney L. Barfield et al.
HUMAN MOLECULAR GENETICS (2014)
A systematic review and meta-analysis on the epidemiology of Duchenne and Becker muscular dystrophy
Jean K. Mah et al.
NEUROMUSCULAR DISORDERS (2014)
The GRADE system: a change in the way of assessing the quality of evidence and the strength of recommendations
Ignacio Neumann et al.
REVISTA MEDICA DE CHILE (2014)
LTBP4 genotype predicts age of ambulatory loss in duchenne muscular dystrophy
Kevin M. Flanigan et al.
ANNALS OF NEUROLOGY (2013)
Proteomics of the Dystrophin-glycoprotein Complex and Dystrophinopathy
Ashling Holland et al.
CURRENT PROTEIN & PEPTIDE SCIENCE (2013)
Importance of SPP1 genotype as a covariate in clinical trials in Duchenne muscular dystrophy
Luca Bello et al.
NEUROLOGY (2012)
Molecular Basis for the Regulation of Angiogenesis by Thrombospondin-1 and-2
Patrick R. Lawler et al.
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2012)
Matrix metalloproteinase-2 ablation in dystrophin-deficient mdx muscles reduces angiogenesis resulting in impaired growth of regenerated muscle fibers
Daigo Miyazaki et al.
HUMAN MOLECULAR GENETICS (2011)
Transforming growth factor (TGF)-β signaling in cardiac remodeling
Marcin Dobaczewski et al.
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY (2011)
TGF-beta Inhibits Muscle Differentiation by Blocking Autocrine Signaling Pathways Initiated by IGF-II
Samantha Gardner et al.
MOLECULAR ENDOCRINOLOGY (2011)
SPP1 genotype is a determinant of disease severity in Duchenne muscular dystrophy
E. Pegoraro et al.
NEUROLOGY (2011)
How to obtain the confidence interval from a P value
Douglas G. Altman et al.
BMJ-BRITISH MEDICAL JOURNAL (2011)
Osteopontin Expression in Cardiomyocytes Induces Dilated Cardiomyopathy
Marie-Ange Renault et al.
CIRCULATION-HEART FAILURE (2010)
Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care
Katharine Bushby et al.
LANCET NEUROLOGY (2010)
Osteopontin promotes fibrosis in dystrophic mouse muscle by modulating immune cell subsets and intramuscular TGF-beta
Sylvia A. Vetrone et al.
JOURNAL OF CLINICAL INVESTIGATION (2009)
The Functional-443T/C Osteopontin Promoter Polymorphism Influences Osteopontin Gene Expression in Melanoma Cells via Binding of c-Myb Transcription Factor
Julia Schultz et al.
MOLECULAR CARCINOGENESIS (2009)
The glucocorticoid receptor N363S polymorphism and steroid response in Duchenne dystrophy
D. M. Bonifati et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2006)
Immunomodulation of TGF-beta1 in mdx mouse inhibits connective tissue proliferation in diaphragm but increases inflammatory response: Implications for antifibrotic therapy
Francesca Andreetta et al.
JOURNAL OF NEUROIMMUNOLOGY (2006)
Polymorphisms in the osteopontin promoter affect its transcriptional activity
F Giacopelli et al.
PHYSIOLOGICAL GENOMICS (2004)
Quantifying heterogeneity in a meta-analysis
JPT Higgins et al.
STATISTICS IN MEDICINE (2002)
Expression of Dp260 in muscle tethers the actin cytoskeleton to the dystrophin-glycoprotein complex and partially prevents dystrophy
LE Warner et al.
HUMAN MOLECULAR GENETICS (2002)
Meta-analysis of observational studies in epidemiology - A proposal for reporting
DF Stroup et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2000)
Share Paper
